IL316776A - Methods of treating Pompe disease - Google Patents

Methods of treating Pompe disease

Info

Publication number
IL316776A
IL316776A IL316776A IL31677624A IL316776A IL 316776 A IL316776 A IL 316776A IL 316776 A IL316776 A IL 316776A IL 31677624 A IL31677624 A IL 31677624A IL 316776 A IL316776 A IL 316776A
Authority
IL
Israel
Prior art keywords
methods
pompe disease
treating pompe
treating
disease
Prior art date
Application number
IL316776A
Other languages
English (en)
Hebrew (he)
Inventor
Jay Barth
Sheela Sitaraman Das
Jeff Castelli
Original Assignee
Amicus Therapeutics Inc
Jay Barth
Sheela Sitaraman Das
Jeff Castelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc, Jay Barth, Sheela Sitaraman Das, Jeff Castelli filed Critical Amicus Therapeutics Inc
Publication of IL316776A publication Critical patent/IL316776A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL316776A 2022-05-05 2023-05-05 Methods of treating Pompe disease IL316776A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263338601P 2022-05-05 2022-05-05
US202263399498P 2022-08-19 2022-08-19
US202263399491P 2022-08-19 2022-08-19
US202263404475P 2022-09-07 2022-09-07
US202263414897P 2022-10-10 2022-10-10
US202263428970P 2022-11-30 2022-11-30
US202263431920P 2022-12-12 2022-12-12
US202263434791P 2022-12-22 2022-12-22
US202363447222P 2023-02-21 2023-02-21
PCT/US2023/066657 WO2023215865A1 (en) 2022-05-05 2023-05-05 Methods for treating pompe disease

Publications (1)

Publication Number Publication Date
IL316776A true IL316776A (en) 2025-01-01

Family

ID=86692686

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316776A IL316776A (en) 2022-05-05 2023-05-05 Methods of treating Pompe disease

Country Status (13)

Country Link
US (1) US20260041744A1 (enExample)
EP (1) EP4518885A1 (enExample)
JP (1) JP2025515159A (enExample)
KR (1) KR20250007602A (enExample)
CN (1) CN119343147A (enExample)
AU (1) AU2023265155A1 (enExample)
CA (1) CA3252291A1 (enExample)
CL (1) CL2024003377A1 (enExample)
CO (1) CO2024016724A2 (enExample)
IL (1) IL316776A (enExample)
MX (1) MX2024013673A (enExample)
TW (1) TW202400212A (enExample)
WO (1) WO2023215865A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006625A1 (en) 2024-06-26 2026-01-02 Amicus Therapeutics, Inc. Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US11382980B2 (en) 2013-10-08 2022-07-12 Taiyo Kagaku Co., Ltd. Oil/fat composition containing polyunsaturated fatty acid
JP6851964B2 (ja) * 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
IL299470B2 (en) * 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) * 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
CN119113091A (zh) * 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
WO2020163480A1 (en) 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
JP2024506346A (ja) * 2021-02-11 2024-02-13 アミカス セラピューティックス インコーポレイテッド 組換えヒト酸性アルファグルコシダーゼ及びその使用

Also Published As

Publication number Publication date
MX2024013673A (es) 2024-12-06
CN119343147A (zh) 2025-01-21
CA3252291A1 (en) 2023-11-09
AU2023265155A1 (en) 2024-12-12
KR20250007602A (ko) 2025-01-14
WO2023215865A1 (en) 2023-11-09
CL2024003377A1 (es) 2025-03-28
US20260041744A1 (en) 2026-02-12
CO2024016724A2 (es) 2025-04-28
JP2025515159A (ja) 2025-05-13
EP4518885A1 (en) 2025-03-12
TW202400212A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
IL288920A (en) Glycolate oxidase inhibitors for the treatment of diseases
ES3066136T3 (en) Methods of treating fabry disease
IL320332A (en) Cancer treatment methods
IL315480A (en) Compounds and methods for treating disease
IL314322A (en) Methods of treating patients with autoantibody-mediated disease
IL308628A (en) Methods for treating type 1 diabetes
IL304273A (en) Compositions and methods for treating Fabry disease
IL317947A (en) Complementary disease treatment methods
ZA202209505B (en) Snare for treating heart diseases
IL321655A (en) LPA1 antagonists for the treatment of interstitial lung disease
IL290770A (en) Compounds and methods for treating oxalate-related diseases
IL327070A (en) Methods for treating cardiovascular diseases
IL326065A (en) Methods of treating medical conditions and diseases
GB202116665D0 (en) Method for the treatment of a scleroderma disease
GB202314641D0 (en) Treatment for batten disease
GB202510775D0 (en) New treatment methods
HK40087059A (en) Method for treating inflammatory bowel disease i
HK40097021A (en) Methods for treating neurological disease
IL325768A (en) Methods for treating neurological diseases
HK40087375A (en) Method for treating inflammatory bowel disease ii
AU2020900742A0 (en) Method for treating inflammatory bowel disease I
GB202314249D0 (en) Compositions and method for treating disease
IL316104A (en) Freeze drying method
HK40079944A (en) Compositions and methods for treating pompe disease
HK40096648A (en) Method for treating ox40 related disease